Defining a novel law of glucose homeostasis under Dapagliflozin usage by mathematical model approach

Not Applicable

• Conditions: type 2 diabetes mellitus

• Registration Number: JPRN-jRCTs051180058
• Lead Sponsor: Sakaguchi Kazuhiko

Brief Summary

In this study, it was revealed that the parameter that most strongly distinguishes between the SGLT2 inhibitor group and the non-SGLT2 inhibitor group is the intensity of gluconeogenesis. This is consistent with previous reports of increased gluconeogenesis in the liver of SGLT2 inhibitor users.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-14
• Study Completion: 2020-09-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

1) Type 2 diabetes mellitus
2) doctor think patients need dapagliflozin
3) non-user of other SGLT2i in one month
4) 20 to 75 years old
5) patients can understand order of take medicine
6) patients can take informed consent
7) fasting glucose controlled under 130 mg/d

Exclusion Criteria

1) Plegnancy
2) a rash which one had in past illness by hypoglycemic agent or insulin
3) type 1 diabetes mellitus include SPIDDM and other diabetes
4) liver dysfunction of high grade
5) renal dysfunction of high grade
6) cardiac dysfunction of high grade
7) user of basal insulin or long-acting GLP-1 receptor agonists
8) a mentally challenged person
9) patient who made recently hypoglycemia
10) patient who dapagliflozin is administrated contraindication
11) patietnt who doctor think inadequate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Parameter calculated from mathematical model

Secondary Outcome Measures

Name	Time	Method
Glucose, insulin, c-peptide, glucagon